{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T10:53:28Z","timestamp":1793962408990,"version":"4.8.0"},"reference-count":45,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"AIRC","doi-asserted-by":"publisher","award":["17217"],"award-info":[{"award-number":["17217"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Campania Regional Government Technology Platform Lotta alle PatologieOncologiche: iCURE","award":["B21C17000030007"],"award-info":[{"award-number":["B21C17000030007"]}]},{"name":"\u201cEpigenetic Hallmarks of Multiple Sclerosis\u201d (acronym Epi-MS) in VALERE 2019 Program","award":["id:415, Merit Ranking Area ERC LS"],"award-info":[{"award-number":["id:415, Merit Ranking Area ERC LS"]}]},{"name":"V:ALERE 2020 \u2013","award":["\u201cCIRCE\u201d D.R. n. 138 del 17\/02\/2020 Program"],"award-info":[{"award-number":["\u201cCIRCE\u201d D.R. n. 138 del 17\/02\/2020 Program"]}]},{"name":"Campania Regional Government FASE2: IDEAL","award":["B63D18000560007."],"award-info":[{"award-number":["B63D18000560007."]}]},{"name":"Proof of Concept POC01_00043-EPICUREPOC01_00043-","award":["B64I19000290008"],"award-info":[{"award-number":["B64I19000290008"]}]},{"name":"P.O.R. CAMPANIA Campania ESF Regional Operational Programme 2014\/2020 Axis III-","award":["B27D18001070006"],"award-info":[{"award-number":["B27D18001070006"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The efficacy and side effects of endocrine therapy in breast cancer (BC) depend largely on estrogen receptor alpha (ER\u03b1) expression, the specific drug administered, and treatment scheduling. Although the benefits of endocrine therapy outweigh any adverse effects in the initial stages of BC, later- or advanced-stage tumors acquire resistance to treatments. The mechanisms underlying tumor resistance to therapy are still not well understood, posing a major challenge for BC patient care. Epigenetic regulation and miRNA expression may be involved in the switch from a treatment-sensitive to a treatment-resistant state and could provide a valid therapeutic strategy for ER\u03b1 negative BC. Here, a hybrid lysine-specific histone demethylase inhibitor, MC3324, displaying selective estrogen receptor down-regulator-like activities in BC, was used to highlight the interplay between epigenetic and ER\u03b1 signaling. MC3324 anticancer action is mediated by microRNA (miRNA) expression regulation, indicating an innovative function for this molecule. Integrated analysis suggests a crosstalk between estrogen signaling, ER\u03b1 interactors, miRNAs, and their putative targets. Specifically, miR-181a-5p expression is regulated by MC3324 and has an impact on cellular levels of ER\u03b1. A comparison of breast tumor versus healthy mammary tissues confirmed the important role of miR-181a-5p in ER\u03b1 regulation and points to its putative predictive function in BC therapy.<\/jats:p>","DOI":"10.3390\/cancers13030543","type":"journal-article","created":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T11:40:48Z","timestamp":1612179648000},"page":"543","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Regulatory Interplay between miR-181a-5p and Estrogen Receptor Signaling Cascade in Breast Cancer"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5517-5519","authenticated-orcid":false,"given":"Rosaria","family":"Benedetti","sequence":"first","affiliation":[{"name":"Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Papulino","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Sgueglia","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"Chianese","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-1084","authenticated-orcid":false,"given":"Tommaso","family":"De Marchi","sequence":"additional","affiliation":[{"name":"Department of Oncology and Pathology, Lund University, SE-221 00 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Iovino","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, Via L. De Crecchio 7, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8428-8763","authenticated-orcid":false,"given":"Dante","family":"Rotili","sequence":"additional","affiliation":[{"name":"Department of Drug Chemistry and Technologies, University of Roma \u2018La Sapienza\u2019, P.le A. Moro n. 5, 00185 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9176-2382","authenticated-orcid":false,"given":"Antonello","family":"Mai","sequence":"additional","affiliation":[{"name":"Department of Drug Chemistry and Technologies, University of Roma \u2018La Sapienza\u2019, P.le A. Moro n. 5, 00185 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Nim\u00e9us","sequence":"additional","affiliation":[{"name":"Department of Oncology and Pathology, Lund University, SE-221 00 Lund, Sweden"},{"name":"Department of Surgery, Sk\u00e5nes University Hospital, 222 29 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6588-698X","authenticated-orcid":false,"given":"Carmela","family":"Dell\u2019 Aversana","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80138 Naples, Italy"},{"name":"Institute of Experimental Endocrinology and Oncology \u201cGaetano Salvatore\u201d (IEOS)-National Research Council (CNR), 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7312-5387","authenticated-orcid":false,"given":"Lucia","family":"Altucci","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0140-6736(18)32252-9","article-title":"Globocan 2018: Counting the toll of cancer","volume":"392","author":"The","year":"2018","journal-title":"Lancet"},{"key":"ref_2","unstructured":"(2020, November 18). American Institute for Cancer Research. Available online: https:\/\/www.aicr.org\/."},{"key":"ref_3","unstructured":"American Cancer Society (2017). Breast Cancer Facts &Figures 2017\u20132018, American Cancer Society, Inc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3389\/fendo.2019.00245","article-title":"Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy","volume":"10","author":"Rani","year":"2019","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1093\/carcin\/21.12.2193","article-title":"Distinct mechanisms of loss of estrogen receptor alpha gene expression in human breast cancer: Methylation of the gene and alteration of trans-acting factors","volume":"21","author":"Yoshida","year":"2000","journal-title":"Carcinogenesis"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40487-018-0062-x","article-title":"Endocrine Therapy for Breast Cancer: A Model of Hormonal Manipulation","volume":"6","author":"Johnston","year":"2018","journal-title":"Oncol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.4155\/fmc.15.93","article-title":"Endocrine therapy resistance in breast cancer: Current status, possible mechanisms and overcoming strategies","volume":"7","author":"Fan","year":"2015","journal-title":"Future Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/bit.26791","article-title":"Dynamic microRNA activity identifies therapeutic targets in trastuzumab-resistant HER2(+) breast cancer","volume":"115","author":"Decker","year":"2018","journal-title":"Biotechnol. Bioeng."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"R279","DOI":"10.1530\/ERC-15-0355","article-title":"Roles for miRNAs in endocrine resistance in breast cancer","volume":"22","author":"Muluhngwi","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12575-018-0082-9","article-title":"microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy","volume":"20","author":"Howard","year":"2018","journal-title":"Biol. Proced. Online"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Loh, H.Y., Norman, B.P., Lai, K.S., Rahman, N., Alitheen, N.B.M., and Osman, M.A. (2019). The Regulatory Role of MicroRNAs in Breast Cancer. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20194940"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13148-018-0587-8","article-title":"The role and mechanisms of action of microRNAs in cancer drug resistance","volume":"11","author":"Si","year":"2019","journal-title":"Clin. Epigenetics"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1002\/1878-0261.12561","article-title":"miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer","volume":"13","author":"Lindholm","year":"2019","journal-title":"Mol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Alexandrova, E., Lamberti, J., Saggese, P., Pecoraro, G., Memoli, D., Cappa, V.M., Ravo, M., Iorio, R., Tarallo, R., and Rizzo, F. (2020). Small Non-Coding RNA Profiling Identifies miR-181a-5p as a Mediator of Estrogen Receptor Beta-Induced Inhibition of Cholesterol Biosynthesis in Triple-Negative Breast Cancer. Cells, 9.","DOI":"10.3390\/cells9040874"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"11584","DOI":"10.1038\/s41598-018-29917-2","article-title":"MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer","volume":"8","author":"Kahraman","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Catalanotto, C., Cogoni, C., and Zardo, G. (2016). MicroRNA in Control of Gene Expression: An Overview of Nuclear Functions. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17101712"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.mce.2015.01.035","article-title":"miRNAs regulated by estrogens, tamoxifen, and endocrine disruptors and their downstream gene targets","volume":"418 Pt 3","author":"Klinge","year":"2015","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"15732","DOI":"10.1073\/pnas.0906947106","article-title":"The estrogen receptor-\u03b1-induced microRNA signature regulates itself and its transcriptional response","volume":"106","author":"Castellano","year":"2009","journal-title":"PNAS"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"36940","DOI":"10.18632\/oncotarget.9230","article-title":"Estrogen regulates miRNA expression: Implication of estrogen receptor and miR-124\/AKT2 in tumor growth and angiogenesis","volume":"7","author":"Jiang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.7150\/thno.11543","article-title":"MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer","volume":"5","author":"Bertoli","year":"2015","journal-title":"Theranostics"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Benedetti, R., Dell\u2019Aversana, C., De Marchi, T., Rotili, D., Liu, N.Q., Novakovic, B., Boccella, S., Di Maro, S., Cosconati, S., and Baldi, A. (2019). Inhibition of Histone Demethylases LSD1 and UTX Regulates ERalpha Signaling in Breast Cancer. Cancers (Basel), 11.","DOI":"10.3390\/cancers11122027"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1021\/jm4012802","article-title":"Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities","volume":"57","author":"Rotili","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"W460","DOI":"10.1093\/nar\/gkv403","article-title":"DIANA-miRPath v3.0: Deciphering microRNA function with experimental support","volume":"43","author":"Vlachos","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"John, B., Enright, A.J., Aravin, A., Tuschl, T., Sander, C., and Marks, D.S. (2004). Human MicroRNA targets. PLoS Biol., 2.","DOI":"10.1371\/journal.pbio.0020363"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.molcel.2010.03.007","article-title":"Genome-wide dissection of microRNA functions and cotargeting networks using gene set signatures","volume":"38","author":"Tsang","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ng1536","article-title":"Combinatorial microRNA target predictions","volume":"37","author":"Krek","year":"2005","journal-title":"Nat. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/ng2135","article-title":"The role of site accessibility in microRNA target recognition","volume":"39","author":"Kertesz","year":"2007","journal-title":"Nat. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.cell.2006.07.031","article-title":"A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes","volume":"126","author":"Miranda","year":"2006","journal-title":"Cell"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Agarwal, V., Bell, G.W., Nam, J.W., and Bartel, D.P. (2015). Predicting effective microRNA target sites in mammalian mRNAs. Elife, 4.","DOI":"10.7554\/eLife.05005"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources","volume":"4","author":"Sherman","year":"2009","journal-title":"Nat. Protoc."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1159\/000485351","article-title":"The Dual Regulatory Role of MiR-181a in Breast Cancer","volume":"44","author":"Yang","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s10549-013-2607-x","article-title":"MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP\/ABCG2)","volume":"139","author":"Jiao","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1038\/onc.2014.180","article-title":"PHLDA1 expression is controlled by an estrogen receptor-NFkappaB-miR-181 regulatory loop and is essential for formation of ER+ mammospheres","volume":"34","author":"Kastrati","year":"2015","journal-title":"Oncogene"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1159\/000354521","article-title":"The function role of miR-181a in chemosensitivity to adriamycin by targeting Bcl-2 in low-invasive breast cancer cells","volume":"32","author":"Zhu","year":"2013","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_35","first-page":"2674","article-title":"miR-181a-5p Inhibits Cancer Cell Migration and Angiogenesis via Downregulation of Matrix Metalloproteinase-14","volume":"75","author":"Li","year":"2015","journal-title":"Mol. Cell. Pathobiol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Grober, O.M., Mutarelli, M., Giurato, G., Ravo, M., Cicatiello, L., De Filippo, M.R., Ferraro, L., Nassa, G., Papa, M.F., and Paris, O. (2011). Global analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulation. BMC Genom., 12.","DOI":"10.1186\/1471-2164-12-36"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1515\/hmbci-2012-0025","article-title":"Co-expression of genes with estrogen receptor-alpha and progesterone receptor in human breast carcinoma tissue","volume":"12","author":"Andres","year":"2012","journal-title":"Horm. Mol. Biol. Clin. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.breast.2014.02.007","article-title":"Gender-associated expression of tumor markers and a small gene set in breast carcinoma","volume":"23","author":"Andres","year":"2014","journal-title":"Breast"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/bioinformatics\/btu597","article-title":"Gene regulatory networks by transcription factors and microRNAs in breast cancer","volume":"31","author":"Qin","year":"2015","journal-title":"Bioinformatics"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s00335-010-9268-4","article-title":"USP32 is an active, membrane-bound ubiquitin protease overexpressed in breast cancers","volume":"21","author":"Akhavantabasi","year":"2010","journal-title":"Mamm. Genome"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1158\/0008-5472.CAN-08-4596","article-title":"Copy number alterations that predict metastatic capability of human breast cancer","volume":"69","author":"Zhang","year":"2009","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Indrieri, A., Carrella, S., Carotenuto, P., Banfi, S., and Franco, B. (2020). The Pervasive Role of the miR-181 Family in Development, Neurodegeneration, and Cancer. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21062092"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4048\/jbc.2014.17.2.143","article-title":"miR-205 and miR-200c: Predictive Micro RNAs for Lymph Node Metastasis in Triple Negative Breast Cancer","volume":"17","author":"Berber","year":"2014","journal-title":"J. Breast Cancer"},{"key":"ref_44","first-page":"955","article-title":"Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients","volume":"38","author":"Ota","year":"2011","journal-title":"Int. J. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1002\/1873-3468.13521","article-title":"HDAC2-dependent miRNA signature in acute myeloid leukemia","volume":"593","author":"Conte","year":"2019","journal-title":"FEBS Lett."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/3\/543\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:18:12Z","timestamp":1760159892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/3\/543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["cancers13030543"],"URL":"https:\/\/doi.org\/10.3390\/cancers13030543","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,1]]}}}